In 2003, Clarke and colleagues demonstrated that a highly tumorigenic subpopulation of BCSCs, expressing CD44+CD24- surface marker in clinical specimen, had the capacity to form tumors with as few as one hundred cells, whereas tens of thousands of the bulk breast cancer cells did not [3]. This evidence concerns the gene CD44 and breast carcinoma.